Summary Dipyridamole (DP) has been shown to reverse multidrug resistance (MDR) via interactions with Pglycoprotein (P-gp). The effect of DP on VP16 growth inhibition was investigated in parental (CHO-KI) and MDR (CHO-AdrD Chinese hamster ovary cells. CHO-Adrr cells were 18-fold resistant to VP16 and intracellular accumulation was 28% less than in CHO-Ki cells. DP reduced the resistance of CHO-Adrr to VP16 by a factor of 2-3 and caused a similar potentiation of VP16 growth inhibition in the parental cells. A time-dependent increase in intracellular VP16 accumulation, which was similar in both cell lines, was caused by DP. The intracellular retention of VP16 was increased 2-to 3-fold by DP in both cell lines. The magnitude of the effect of DP on all three parameters measured was similar (2-to 4-fold), suggesting that the increased growth inhibition was related to increased intracellular exposure to VP16 owing to the inhibition of the efflux of VP16 by DP. However, since the effect of DP was similar in both parental and P-gp-overexpressing cells it is unlikely that the potentiation of VP16 by DP is mediated via an interaction with P-gp.
Multidrug resistance (MDR) severely compromises the efficacy of cancer chemotherapy in the clinic. It occurs when tumours, which may initially have been sensitive, become resistant to a variety of anti-cancer drugs. In experimental models this type of resistance is characterised by reduced sensitivity to a range of structurally unrelated chemotherapeutic agents with diverse subcellular targets. This spectrum of drugs includes many therapeutically important natural products and their semisynthetic congeners and includes the anthracyclins, the vinca alkaloids and the epipodophyllotoxins. In vitro studies show that MDR is accompanied by reduced intracellular drug accumulation mediated by increased drug efflux. Overexpression of a plasma membrane efflux pump, the p170 glycoprotein (P-gp), the product of the mdrl gene, has been demonstrated in many cells with the MDR phenotype and transfection of mdr cDNA can confer the MDR phenotype through P-gp overexpression (Endicott and Ling, 1989 and references therein). Inhibitors of P-gp can therefore resensitise MDR cells, and many studies have been conducted into the use of P-gp inhibitors as modulators of MDR (Wigler and Patterson, 1993) .
Dipyridamole (DP), because of its known interaction with nucleoside transport (Plagemann et al., 1988; Belt et al., 1993) , has been most extensively studied as an augmentor of antimetabolite cytotoxicity (Schmoll et al., 1990; Goel and Howell, 1991 and references therein) . Nevertheless, several studies have demonstrated the potentiation of other agents by DP. Ramu et al. reported in 1984 that DP increased the cytotoxicity of doxorubicin 15-fold in an MDR subline but only 2-fold in the parental cell line. Since then several studies have demonstrated the potentiation of a variety of MDR drugs by DP (reviewed by Goel and Howell, 1991) . There is good evidence to show that this is mediated via an interaction of DP with P-gp. DP has been shown to increase the steadystate intracellular concentration and cytotoxicity of both vincristine and actinomycin D, and this was associated with the inhibition of drug efflux, to a far greater extent in MDR variants than the parental cells (Asoh et al., 1989) . Furthermore, DP inhibited the photoaffinity labelling of Pgp with [3H]azidopine (Asoh et al., 1989) .
The mechanism of the interaction of DP with the cellular response to VP16 is less clear. VP16 (etoposide), an epipodophyllotoxin derivative inhibitor of topoisomerase II, is usually included in the MDR phenotype, although its transport characteristics and relationship to P-gp are not as well characterised as the anthracyclins or vinca alkaloids. DP has been shown to increase the intracellular concentration of VP16 in both mdr-transfected cells and parental cells but this was not associated with a synergistic increase in VP16 cytotoxicity (Shalinsky et al., 1990) . In other studies DP enhanced the cytotoxicity, as well as increasing the intracellular accumulation and decreasing the efflux, of VP16 in the drug-sensitive 2008 cell line (Howell et al., 1989a, b) . In order to investigate further the role of DP-P-gp interactions in the potentiation of VP16 cytotoxicity we have measured the effects of DP on the cellular pharmacology of VP16 in parental CHO-KI cells and the MDR subline CHOAdrr. This cell line was derived by exposure to increasing concentrations of doxorubicin and has been well characterised (Hoban et al., 1992 
Growth inhibition assays
Cells were seeded at 1 -1.5 x I03 cells per well in 100 yl of medium in replicate 96-well plates (leaving the outer wells with 100 MI of medium alone to minimise 'edge effect') and allowed to attach overnight. After 16-24 h the medium was replaced with that containing varying concentrations of VP16 with or without 10 JiM DP in a final DMSO concentration of 0.1%, ten replicate wells were used for each drug concentration. A replicate plate was fixed as described below to obtain an estimate of the cell density at the start of the drug incubation. The plates were incubated for 72 h at 37C before assaying for cell growth as described previously (Skehan et al., 1990) . Briefly, the 96-well plates were fixed in ice-cold 10% trichloroacetic acid (TCA) followed by icecold methanol, washed in tap water and air dried. The plates (together with the preincubation plate) were stained with 0.4% (w/v) sulphorhodamine B (Sigma) in 1% acetic acid (100 MI per well) for 30 min then rinsed three times in 1% acetic acid to remove unbound stain. Protein-bound stain was extracted using 100 MI of 10 mM Tris base (Sigma) per well.
The optical density of the wells was read on a computerinterfaced MR700 microtitre plate reader (Dynatech, Billingshurst, West Sussex, UK) relative to an air blank using a 570 nm filter.
Measurement of [3H]VPJ6 accumulation
In order to mimic the conditions for growth inhibition as closely as possible the accumulation of VP16 was measured in complete medium rather than buffer. Cells were harvested without trypsin, using EDTA in phosphate-buffered saline (PBS), to avoid the proteolytic digestion of plasma membrane proteins. The cells were resuspended at 2 x 107 ml-' in complete medium with or without 10 gM DP. [3H]VP16 was added to give a final concentration of 10 jg ml-' (17 gM: 1.1 mCi LM-') and mixed vigorously. The cells were agitated at room temperature and triplicate 50 yl (i.e. 106 cells) samples were spun through 100 of silicone oil, specific gravity 1.028 (Dow-Corning 556:550 9:11; BDH, Merck, Lutterworth, Leicestershire, UK) overlaying 50 ul of 3 M potassium hydroxide in microfuge tubes (0.4 ml, BDH) at intervals. The tubes were capped and cut in the silicone layer; the lower portion, containing the cells lysed in potassium hydroxide, was placed in scintillation vials. The intracellular 3H was measured, following neutralisation of the cell lysate with 0.25 M acetic acid, by scintillation counting on an LKB-Wallac S1410 #- (Figure 2 ). In the absence of DP, steady-state concentrations of VP16 were reached within the first 5 min of incubation in both cell lines. The MDR CHOAdrr cells accumulated significantly less VP16 than the wildtype CHO-KI cells. However, the intracellular VP16 concentration was only 28+5% less in CHO-Adrr cells than in CHO-KI cells. In the presence of DP, VP16 continued to accumulate so that steady-state levels had still not been reached by 60 min. DP effectively increased VP16 content relative to controls in both cell lines (Table II) Thereafter the rate of efflux was slower. DP retarded the efflux of VP16 in both cell lines, this effect was primarily on the initial rapid efflux phase. DP had a slightly greater effect on the CHO-Adrr cells at 1 min, but this was not significant and thereafter the magnitude of the effect mediated by DP was remarkably similar in both lines (Table III) . These studies show that the CHO-Adrr cell line is approximately 18-fold resistant to VP16. However, in drug accumulation studies the intracellular steady-state level of VP16 in CHO-Adrr cells was only 28% lower than in CHO-KI cells, in contrast to the 5-fold reduced doxorubicin accumulation reported for these cells (Hoban et al., 1992) . This suggests that the resistance to VP16 in CHO-Adrr cells was mainly due to other mechanisms, probably the 4-fold reduction in topoisomerase II activity also reported for this cell line (Hoban et al., 1992) .
CHO-Adrr cells have been reported to have a 4-fold amplification of the mdrl gene and marked P-gp overexpression that results in a 5-fold increase in doxorubicin efflux in CHO-Adrr cells compared with the parental cells (Hoban et al., 1992) . However, VP16 retention is not significantly different in CHO-Adrr from that in CHO-KI cells after 5 min in drug-free medium (Figure 3 ). These data suggest that P-gp plays only a modest role in the efflux of VP16. Additional evidence suggests that, although VP16 is recognised by P-gp, it is a poor substrate, for example in a study of 13 VP16-resistant CHO sublines none overexpressed P-gp (Soues et al., 1995) . Other studies have shown that r_ 858 r%, 859 verapamil, an MDR antagonist, does not increase the retention of VP16 in P-gp-overexpressing Chinese hamster lung cells (that accumulate 2-to 4-fold less VP16 than the parental cells) indicating that P-gp was not important in the efflux of VP16 (Politi et al., 1990) . Moreover, VP16 is a poor inhibitor of the photoaffinity labelling of P-gp by either azidopine (Sehested et al., 1992 ) or verapamil (Politi et al., 1990 .
The effect of DP on the efflux of, the accumulation of and the sensitivity to VP16 was essentially the same in both CHOKl and CHO-Adrr cells. This is in marked contrast to the effect of verapamil, which has been shown to increase the accumulation of and sensitivity to doxorubicin to a far greater extent in CHO-Adrr cells than CHO-Kl cells (Chatterjee et al., 1990; Hoban et al., 1992) . In these studies verapamil also augmented the accumulation and cytotoxicity of doxorubicin in the parental CHO-KI cells to a small extent, presumably owing to the intrinsic moderate expression of P-gp in wild-type CHO cells (Gupta, 1988) . Nevertheless, if DP was sensitising cells to VP16 via a P-gp mechanism, a greater effect on CHO-Adrr cells than CHO-Kl cells would be expected. DP increased VP16 retention 2-to 3-fold, accumulation 3-to 4-fold and growth inhibition 2-to 4-fold, i.e. the magnitude of the effect of DP was similar on all three parameters. The implication is that the DP-mediated effect on growth inhibition is due to increased cellular exposure to VP16, which is related to the reduction in efflux. DP does appear to be acting via the inhibition of VP16 efflux but to the same extent in both cell lines. This implies that it is acting on an efflux mechanism that is not overexpressed in CHOAdrr cells compared with the parental cells. Strikingly similar effects of DP on VP16 accumulation, retention and cytotoxicity have been reported by Howell et al. (1989b) for the drug-sensitive human ovarian carcinoma cell line, 2008. Furthermore these authors demonstrated that the synergy between DP and VP16 was not due to displacement of VP16 from serum proteins by DP. Similarly, Shalinsky et al. (1990) observed that DP increased the intracellular steady-state concentration of VP16 in cells that do not overexpress P-gp and concluded that DP could potentiate MDR drugs by both P-gp-dependent and P-gp-independent mechanisms.
The inhibition of VP16 efflux by a mechanism that is not overexpressed in CHO-Adrr cells (P-gp-independent) could be due to an effect of DP on the passive diffusion of VP16 across the plasma membrane. However, CHO-Kl and CHOAdre cells maintain lower intracellular concentrations of VP16 in the absence of DP than in its presence ( Figure 2 ) and DP is known to interact with a variety of plasma membrane transporter proteins (e.g. nucleoside transporter, glucose transporter, P-gp). Thus, it is also possible that DP is inhibiting a VP16 efflux transporter protein that is expressed to the same extent in both CHO-KI and CHO-Adrr cells. Recent studies (Soues et al., 1995) using CHO sublines isolated by resistance to VP16 found that in two highly resistant sublines there was neither reduced topoisomerase II nor increased P-gp expression, suggesting the possible overexpression of another, unidentified, efflux transporter. Other studies demonstrate that novobiocin can potentiate VP16 cytotoxicity in non-P-gp-overexpressing multidrugresistant cell lines, mediated through the intracellular accumulation of VP16, but in P-gp-overexpressing cell lines novobiocin increased neither the intracellular accumulation nor the cytotoxicity of VP16 (Rappa et al., 1993) .
It is now becoming clear that P-gp is not the only plasma membrane drug efflux protein. At least one other protein, the multidrug resistance protein, MRP (Cole et al., 1992) , also confers resistance to natural product anti-cancer drugs. There is evidence to suggest that, whereas VP16 is a poor substrate for P-gp (Politi et al., 1990; Sehested et al., 1992; Soues et al., 1995) , it is a good substrate for MRP, namely in MCF7 cells made resistant to VP16 MRP mRNA was increased at least 10-fold (Schneider et al., 1994) and in two HeLa sublines transfected with MRP the resistance to VP16 (11.6-and 8.9-fold) was greater than that for most of the other drugs evaluated (Cole et al., 1994) . It is tempting to speculate that DP augmentation of VP16 in CHO-Ki and CHO-Adrr cells may be mediated through inhibition of MRP. CHO-KI cells have a modest overexpression of P-gp (Gupta, 1988) before selection for drug resistance: it is possible that they might also express MRP and that this level of expression was not increased during the selection for resistance to doxorubicin. However, in a VP16-resistant human ovarian cell line neither P-gp nor MRP overexpression was detected despite reduced drug accumulation in these cells (Kubota et al., 1994) , which might indicate the existence of yet another drug efflux protein that could be a target for DP. Future studies using an MRPoverexpressing line will be necessary to address this question.
Abbreviations MDR, multidrug resistance; DP, dipyridamole; P-gp, P-glycoprotein; DMSO, dimethyl sulphoxide; TCA, trichloroacetic acid; IC50, concentration that inhibits cell growth to 50% of control growth; DEF50, dose enhancement factor at the IC50-
